AKEBIA THERAPEUTICS INC's ticker is AKBA and the CUSIP is 00972D105. A total of 90 filers reported holding AKEBIA THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,993,096 | +59650.1% | 3,914,800 | +7.2% | 0.01% | -36.4% |
Q1 2024 | $6,683 | +12.8% | 3,652,100 | -23.6% | 0.01% | +22.2% |
Q4 2023 | $5,926 | +64.7% | 4,779,383 | +51.5% | 0.01% | +50.0% |
Q3 2023 | $3,597 | +18.0% | 3,155,427 | -5.3% | 0.01% | +50.0% |
Q2 2023 | $3,048 | +132.7% | 3,330,727 | +42.4% | 0.00% | +100.0% |
Q1 2023 | $1,310 | -21.3% | 2,338,500 | -19.0% | 0.00% | 0.0% |
Q4 2022 | $1,665 | -99.8% | 2,886,227 | -4.3% | 0.00% | +100.0% |
Q3 2022 | $954,000 | +82.4% | 3,016,427 | +103.5% | 0.00% | 0.0% |
Q2 2022 | $523,000 | -27.4% | 1,482,300 | +47.7% | 0.00% | 0.0% |
Q1 2022 | $720,000 | -48.9% | 1,003,327 | +61.0% | 0.00% | -50.0% |
Q4 2021 | $1,408,000 | -48.5% | 623,027 | -34.4% | 0.00% | -50.0% |
Q3 2021 | $2,736,000 | -60.5% | 949,927 | -48.0% | 0.00% | -55.6% |
Q2 2021 | $6,927,000 | +91.1% | 1,827,730 | +70.7% | 0.01% | +80.0% |
Q1 2021 | $3,624,000 | -10.6% | 1,070,581 | -26.1% | 0.01% | +25.0% |
Q4 2020 | $4,054,000 | +2203.4% | 1,447,927 | +1963.3% | 0.00% | – |
Q3 2020 | $176,000 | -82.9% | 70,175 | -7.3% | 0.00% | -100.0% |
Q2 2020 | $1,028,000 | +17.5% | 75,689 | -45.4% | 0.00% | 0.0% |
Q4 2019 | $875,000 | +414.7% | 138,527 | +219.0% | 0.00% | – |
Q3 2019 | $170,000 | -98.9% | 43,427 | -97.6% | 0.00% | -100.0% |
Q3 2018 | $15,691,000 | -63.3% | 1,776,971 | -59.6% | 0.02% | -30.4% |
Q2 2018 | $42,716,000 | +77.9% | 4,393,700 | +74.4% | 0.02% | -11.5% |
Q1 2018 | $24,007,000 | -11.4% | 2,519,100 | +38.3% | 0.03% | -13.3% |
Q4 2017 | $27,081,000 | -3.1% | 1,821,200 | +28.2% | 0.03% | -9.1% |
Q3 2017 | $27,949,000 | +89.7% | 1,420,900 | +38.6% | 0.03% | +73.7% |
Q2 2017 | $14,734,000 | +314.6% | 1,025,300 | +165.4% | 0.02% | +280.0% |
Q1 2017 | $3,554,000 | +63.6% | 386,267 | +85.2% | 0.01% | +66.7% |
Q4 2016 | $2,172,000 | +58.1% | 208,600 | +37.4% | 0.00% | +50.0% |
Q3 2016 | $1,374,000 | +654.9% | 151,800 | +524.7% | 0.00% | – |
Q2 2016 | $182,000 | -29.2% | 24,300 | -14.7% | 0.00% | – |
Q1 2016 | $257,000 | -81.8% | 28,500 | -73.9% | 0.00% | -100.0% |
Q4 2015 | $1,411,000 | +32.0% | 109,200 | -1.4% | 0.00% | 0.0% |
Q3 2015 | $1,069,000 | -72.8% | 110,700 | -71.0% | 0.00% | -66.7% |
Q2 2015 | $3,923,000 | – | 381,239 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 4,652,561 | $13,027,000 | 5.13% |
Orchard Capital Management, LLC | 857,138 | $2,400,000 | 1.02% |
Nantahala Capital Management | 7,040,487 | $19,713,000 | 0.61% |
OCCUDO QUANTITATIVE STRATEGIES LP | 209,040 | $585,000 | 0.18% |
Woodline Partners LP | 2,382,522 | $6,671,000 | 0.18% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,546,169 | $4,329,000 | 0.15% |
Virtus ETF Advisers LLC | 92,771 | $260,000 | 0.11% |
Jump Financial, LLC | 155,583 | $435,000 | 0.07% |
GSA CAPITAL PARTNERS LLP | 128,626 | $360,000 | 0.06% |
Anson Funds Management LP | 95,342 | $267,000 | 0.05% |